Radioiodine diagnosis and treatment are based on iodine uptake into differentiated thyroid cancer cells by the sodium/iodide symporter (NIS), and this theranostic strategy is applicable for NIS-expressing cancers including metastatic regions. This evidence concerns the gene SLC5A5 and thyroid gland carcinoma.